Manjula Tella, MD
Neurology · Fremont, NENPI 1811050644
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 49.4% of the total. Reporting peaked in 2020 at $1,753 and has fallen 94.1% since, to $103 in 2024.
Across 342 payments — averaging $13.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- Biogen$449
- AbbVie$425
- Teva Pharmaceuticals USA, Inc.$280
- Lilly USA, LLC$162
- Biohaven Pharmaceuticals, Inc.$161
- plus $819 from 19 others
What the payments were for
- Consulting fees$3007%
- Speaking & faculty fees$1,50033%
- Food & beverage$2,51555%
- Education$2235%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 144 | $2,241 |
| Biogen | 22 | $449 |
| AbbVie | 63 | $425 |
| Teva Pharmaceuticals USA, Inc. | 16 | $280 |
| Lilly USA, LLC | 12 | $162 |
| Biohaven Pharmaceuticals, Inc. | 13 | $161 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $159 |
| Novartis | 23 | $154 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Mallinckrodt Hospital Products Inc. | 3 | $65 |
| Neurocrine Biosciences, Inc. | 3 | $47 |
| MDD US Operations, LLC | 3 | $44 |
| SK Life Science, Inc. | 3 | $44 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Lundbeck LLC | 2 | $32 |
| Acorda Therapeutics, Inc | 2 | $31 |
| Neurelis, Inc. | 1 | $31 |
| UCB, Inc. | 1 | $24 |
| Avion Pharmaceuticals | 1 | $13 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Upsher-smith Laboratories LLC | 1 | $12 |
| EMD Serono, Inc. | 1 | $12 |
| GE HealthCare | 1 | $9 |
| GRT US Holding, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TROKENDI XR$1,500
- TYSABRI$300
How this compares
$4,537 in reported general payments places this provider in the 70th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 16 | $101,304 |
| Aimovig AutoinjectorErenumab-Aooe | 111 | $87,639 |
| QuliptaAtogepant | 60 | $70,779 |
| UbrelvyUbrogepant | 28 | $46,876 |
| NourianzIstradefylline | 25 | $46,474 |
| BriviactBrivaracetam | 29 | $40,978 |
| Emgality PenGalcanezumab-Gnlm | 50 | $36,066 |
| Nurtec OdtRimegepant Sulfate | 29 | $32,551 |
| GocovriAmantadine Hcl | 12 | $29,170 |
| FycompaPerampanel | 20 | $23,795 |
| RytaryCarbidopa/Levodopa | 53 | $16,262 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 249 | $8,946 |
| SavellaMilnacipran Hcl | 15 | $8,374 |
| OngentysOpicapone | 12 | $7,999 |
| Memantine Hcl | 370 | $6,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Savella | $425 | $126,029103 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $280 | $101,30416 claims |
| UCB, Inc.Briviact | $24 | $40,97829 claims |
| MDD US Operations, LLCGocovri | $44 | $29,17012 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $43 | $17,49466 claims |
| Neurocrine Biosciences, Inc.Ongentys | $47 | $7,99912 claims |
| Upsher-smith Laboratories LLCTopiramate | $12 | $2,723302 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 105 neurology providers in Nebraska.
Other neurology in Fremont
- John PuenteFremont$179K
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Gary PatteeLincoln$132K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.